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Background: Amelogenins are a complex mixture of hydrophobic proteins that are the major organic com-
ponent of developing enamel. The principal function of the amelogenins and their degradation products has
been assigned to structural roles in creating the space and milieu for promoting enamel mineralization.
Enamel matrix derivative (EMD) has been used clinically for periodontal regeneration and its therapeutic
effectiveness has been attributed to amelogenin, non-amelogenin enamel matrix proteins, and growth factors.
While EMD is believed to induce periodontal regeneration, the precise mechanism is not known. Bone sialo-
protein (BSP), an early phenotypic marker of osteoblast and cementoblast differentiation, has been impli-
cated in the nucleation of hydroxyapatite during bone formation. In this study, we examined the ability of
amelogenin to regulate BSP gene transcription in osteoblast like cells.
Methods: We conducted Northern hybridization, transient transfection analyses, and gel mobility shift
assays using full-length recombinant amelogenin to determine the molecular basis of the transcriptional reg-
ulation of BSP gene by amelogenin.
Results: Recombinant amelogenin (1 µg/ml, 12 hours) increased BSP mRNA levels ~2.4-fold. In transient
transfection analyses, amelogenin (1 µg/ml, 12 hours) increased luciferase activity ~1.5-fold in pLUC3
(nucleotides −116 to +60) and further increased pLUC5 (nucleotides −801 to +60) activity ~2.3-fold trans-
fected into ROS 17/2.8 cells. Amelogenin also increased luciferase activities in rat stromal bone marrow cells.
The effect of amelogenin was inhibited by the tyrosine kinase inhibitor herbimycin A. Transcriptional stimu-
lation by amelogenin was almost completely abrogated in cells expressing a BSP promoter construct with a
mutation in the fibroblast growth factor 2 (FGF2) response element (FRE). Gel mobility shift assays with radio-
labeled FRE and transforming growth factor-β1 (TGF-β1) activation element (TAE) ds-oligonucleotides
revealed increased binding of nuclear proteins from amelogenin-stimulated ROS 17/2.8 cells.
Conclusion: Amelogenin stimulation alters BSP gene transcription by inducing nuclear proteins that bind to
the FRE and TAE in the rat BSP gene promoter. J Periodontol 2005;76:1482-1489.
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Amelogenins constitute 90% of the extracellularmatrix secreted by ameloblasts, and the pro-teins are cleaved in a regulated process during
enamel maturation.1,2 It has been suggested that these
proline-rich proteins play a role in the mineralization
and structural organization of developing enamel.3
Amelogenin is a cell adhesion protein,4 a potential
regulator of cementum-associated genes such as bone
sialoprotein (BSP) and type I collagen, and specific
amelogenin gene splice products may be tissue-
specific epithelial mesenchymal signaling molecules.5
Alternative splicing of the primary transcript as a
potential mechanism for generating amelogenin het-
erogeneity.6 Amelogenin-deficient mice display an
amelogenesis imperfecta phenotype, showed root
resportion, and reduced expression of BSP.7-9 Enamel
matrix derivative (EMD), the acid extracts of porcine
cheese-like enamel matrix, has been developed as a
clinical treatment to promote periodontal regenera-
tion.10,11 Approximately 90% of the protein in the EMD
is amelogenins, and the remaining 10% is comprised
of non-amelogenin enamel matrix proteins and growth
factors.12-14
BSP is a mineralized tissue-specific protein that is
glycosylated, phosphorylated, and sulfated.15,16 BSP
nucleates hydroxyapatite crystal formation17,18 and is
expressed in several malignant cancers where it is
associated with the formation of ectopic hydroxyapatite
microcrystals.19,20 To study the transcriptional regu-
lation of BSP, rat, human, and mouse BSP gene pro-
moters were cloned and characterized.21-24 These
promoters include an inverted TATA box25 overlap-
ping a vitamin D response element,26 an inverted
CCAAT box (−50 to −46), which is bound with NF-Y
transcription factor.27,28 A cAMP response element
(CRE; −75 to −68),29,30 a fibroblast growth factor 2
response element (FRE; −92 to −85),30-32 a pituitary-
specific transcription factor-1 (Pit-1) motif (−111 to
−105) which mediates the stimulatory effects of para-
thyroid hormone,32,33 and a homeodomain binding
element (HOX; −199 to −192) have been character-
ized.11,34 Further upstream in the rat promoter a trans-
forming growth factor-β (TGF-β activation element
(TAE; −499 to −485)11,35 and a glucocorticoid res-
ponse element (−920 to −906), overlapping an activa-
tor protein (AP)-1 site (−921 to −915) have also been
identified.16,36
Although EMD is used clinically, little is known about
amelogenin effects on bone metabolism. Therefore,
we wish to determine the effect of amelogenin on BSP
gene expression. The aim of the present study was to
evaluate the ability of amelogenin to regulate osteoblast
specific gene expression such as BSP. In this study we
show that amelogenin regulates BSP expression in
osteoblast-like ROS 17/2.8 cells through FRE and TAE
in the rat BSP promoter.
MATERIALS AND METHODS
Cell Culture
The rat osteoblast-like ROS 17/2.8 cells37 and rat stro-
mal bone marrow cells (SBMC)38 were maintained in
alpha minimum essential medium (α-MEM)§ contain-
ing 10% fetal calf serum (FCS).§ Cells were grown to
confluence in 60 mm tissue culture dishes and then
cultured in α-MEM without serum and incubated with
or without recombinant amelogenin for time periods
extending from 3 to 12 hours. RNA was isolated from
triplicate cultures at various time intervals and ana-
lyzed for the expression of BSP mRNA by Northern
hybridization as described below.
Preparation of Recombinant Porcine Amelogenin
Recombinant porcine amelogenin (rP172) was expressed
from the pET11 expression vector in E. coli BL21(DE3)
cells and purified from E. coli extracts by selective pre-
cipitation in ammonium sulfate (20% saturation), fol-
lowed by ion exchange chromatography, followed by
separation on a C4 reversed-phase column.3
Northern Hybridization
Aliquots (20 µg) of total RNA were fractionated on 1.2%
agarose gel and transferred onto a hybond-N+ mem-
brane.¶ Hybridizations were performed at 42°C with
either a 32P-labeled rat BSP, osteopontin (OPN), or gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA probe. Following hybridization, membranes were
washed four times for 5 minutes each at 21°C in
300 mM sodium chloride and 30 mM trisodium citrate
pH 7.0 containing 0.1% sodium dodecyl sulfate. This was
followed by two 20 minute washes at 55°C in 15 mM
sodium chloride and 1.5 mM trisodium citrate pH 7.0,
0.1% SDS. The hybridized bands were scanned in an
imaging analyzer# and normalized to the expression of
GAPDH.31
Transient Transfection Assays
Exponentially growing cells were used for transfection
assays. Twenty-four hours after plating, cells at 50%
to 70% confluence were transfected using a lipo-
fectamine reagent.** The transfection mixture in-
cluded 1 µg of a luciferase (LUC) construct16 and
2 µg pSV-ß-galactosidase (ß-gal) vector†† as an
internal control to normalized for individual trans-
fection efficiencies. Two days post-transfection, cells
were deprived of serum for 12 hours and recombi-
nant amelogenin (1 µg/ml) was added and the cells
cultured for a further 12 hours prior to harvesting.
The luciferase assay was performed according to the
§ GIBCO BRL Life Technologies, Tokyo, Japan.
 Stratagene, La Jolla, CA.
¶ Amersham Biosciences, Piscataway, NJ.
# Fuji BAS 2000, Fuji film, Tokyo, Japan.
** Invitrogen Corp., Carlsbad, CA.
†† Promega Corp., Madison, WI.
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Figure 1.
Northern hybridization analysis of recombinant amelogenin effects on
BSP mRNA expression. A) Dose-response effect of amelogenin on
BSPmRNA levels in the osteoblastic cell line ROS17/2.8 treated for
12 hours.At 0.01 to 10 µg/ml, amelogenin increased BSPmRNA with
a maximal effect at 1 µg/ml. B) Twelve-hour time-course revealed an
increase in BSP mRNA at 3 and 12 hours after the administration of 1
µg/ml amelogenin to ROS17/2.8 cells.Total RNA was isolated from
triplicate cultures harvested after incubation times of 3, 6, and
12 hours and used for Northern hybridization analysis using a
32P-labeled rat BSP DNA probe, an osteopontin DNA probe, and a
GAPDH DNA probe.
supplier’s protocol‡‡ using a luminescence reader§§
to measure the luciferase activity. The protein kinase
inhibitor H89 (5 µM) and H7 (5 µM) was used to
inhibit protein kinase A and C. Herbimycin A (1 µM)
was used for tyrosine kinase inhibitior.30,31 Oligonu-
cleotide-directed mutagenesis by polymerase chain
reaction (PCR) was utilized to introduce dinucleo-
tide substitutions using a site-directed mutagenesis
kit. All constructs were sequenced as described
previously to verify the fidelity of the mutagenesis.31
Gel Mobility Shift Assays
Confluent ROS 17/2.8 cells in T-75 flasks incubated for
3 and 12 hours with amelogenin (1 µg/ml) in α-MEM
without serum were used to prepare nuclear extracts
as described previously.33 Double-stranded oligonu-
cleotides encompassing the inverted CCAAT (nucleo-
tides −61 to −37, 5′-CCGTGACCGTGATTGGCTGCT
GAGA), FGF2 response element (FRE; nucleotides 
−98 to −79, 5′-TTTTCTGGTGAGAACCCACA), homeo-
domain binding element (HOX; nucleotides −204 to 
−179, 5′-TCCTCAGCCTTCAATTAAATCCCACA) and
TGF-β activation element (TAE; nucleotides −506 to 
−482, 5′-CAAAGCCTTGGCAGCCCGGCTGGCT) in the
rat BSP promoter were prepared commercially,  while
consensus NF1 (5′-CCTTTGGCATGCTGCCAATAT)
were purchased.†† For gel shift analysis the double-
stranded oligonucleotides were end-labeled with [γ-32P]
ATP and T4 polynucleotide kinase. Nuclear protein
extracts (3 µg) were incubated for 20 minutes at room
temperature (RT = 21°C) with 0.1 pM radiolabeled
double-stranded-oligonucleotide in buffer containing
50 mM KCl, 0.5 mM EDTA, 10 mM Tris-HCl (pH 7.9),
1 mM DTT, 0.04% nonidet P-40, 5% glycerol, and 1 µg
poly (dI-dC). Following incubation, the protein-DNA
complexes were resolved by electrophoresis on 5% non-
denaturing acrylamide gels (38:2 acrylamide/bis acry-
lamide) run at 150 V at RT. Following electrophoresis,
the gels were dried and autoradiograms prepared and
analyzed using an imaging analyzer.
Statistical Analysis
Triplicate samples were analyzed for each experiment
and experiments replicated to ensure consistency of the
responses to amelogenin. Significant differences
between control and amelogenin treatment were
determined using the Student t test.
RESULTS
Stimulation of BSP mRNA Expression in ROS
17/2.8 Cells
To study the regulation of BSP expression by amelo-
genin, we performed Northern hybridization analysis
of total RNA extracted from osteoblastic ROS 17/
2.8 cells. First, a dose-response relation for amelo-
genin induction of BSP was established by treating
the ROS 17/2.8 cells with different concentrations
of recombinant amelogenin for 12 hours. Amelogenin
increased BSP mRNA levels at 0.01~1 µg/ml and had
a maximal effect at 1 µg/ml (~2.4-fold) (Fig. 1A).
Thus, 1 µg/ml amelogenin was used to determine the
time course of BSP mRNA expression (Fig. 1B). Amelo-
genin upregulated BSP mRNA accumulation at 12 hours,
whereas no effect on OPN and GAPDH mRNA was
observed.
‡‡ PicaGene, Toyo Inki, Tokyo, Japan.
§§ Aloka, Tokyo, Japan.
  Bio-Synthesis, Inc., Lewisville, TX.
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possible response elements encoded within nucleo-
tides −116 to −43 of pLUC3 as shown in Figure 6.
Whereas mutations in the CRE (M-CRE) and Pit-1
(M-PIT) had no effect on amelogenin stimulation,
Transient Transfection Analysis
of Rat BSP Promoter
Constructs
Transient transfection of chimeric
constructs, encompassing differ-
ent regions of the rat BSP pro-
moter driving a luciferase reporter
gene (pLUC1~pLUC5), were per-
formed in ROS 17/2.8 cells. The re-
sults of transfection assays (Fig. 2)
indicated a ~1.5-fold (pLUC3; −116
to +60), ~1.5-fold (pLUC4; −425
to +60) and ~2.3-fold (pLUC5; −801
to +60) increase in transcription
with the luciferase constructs after
12 hours of treatment with 1 µg/ml
amelogenin. In shorter constructs
(pLUC1; −18 to +60, pLUC2; −43
to +60), luciferase activities were
not increased by amelogenin.
When transcriptional activities in
response to amelogenin were ana-
lyzed in normal rat SBMC, the
transcriptional activities of pLUC3
(~1.5-fold), pLUC4 (~1.5-fold) and
pLUC5 (~1.7-fold) were increased
(Fig. 3). Included within the DNA
sequence that is unique to pLUC3
construct (nucleotides −116 to −43)
is an inverted CCAAT box (ATTGG;
between nucleotides −50 and −46),
a CRE (between nucleotides −75
and −68), FRE (between nucleotides 
−92 and −85), and a Pit-1 motif (be-
tween nucleotides −111 and −105)
(Fig. 4). There are HOX (TCAAT-
TAAAT, nucleotides −194 to −185)
and TGF-β activation elements
(TAE; CTTGGCAGCCCGGCTGG,
nucleotides −500 to −484) in the
pLUC4 and pLUC5 which were
identified as enamel matrix deriv-
ative (EMD) response elements in
the previous study (Fig. 4).11 Since
protein kinases mediate amelo-
genin signaling, we also investi-
gated the effects of the protein
kinase C inhibitor H7, the protein
kinase A inhibitor H89, and the
tyrosine kinase inhibitor HA on
amelogenin-mediated transcrip-
tion. Although amelogenin induc-
tion of pLUC3 promoter activity was inhibited by HA,
no effects were observed for PKC and PKA (Fig. 5),
indicating involvement of tyrosine kinase in the sig-
naling pathway. Next we introduced mutations in the
Figure 2.
Amelogenin upregulates BSP promoter activity.Transient transfections of ROS 17/2.8 cells, in the
presence or absence of amelogenin (1 µg/ml) for 12 hours, were used to determine transcriptional
activity of chimeric constructs that included various regions of the BSP promoter ligated to a
luciferase reporter gene.The results of transcriptional activity obtained from three separate
transfections with constructs; pLUC basic (pLUCB) and pLUC1 to pLUC5 have been combined and
the values expressed with standard errors. *Significant differences from control (relative luciferase
activity of pLUCB), P <0.1.
Figure 3.
Transient transfections of rat stromal bone marrow cells. SBMC cells treated with or without
amelogenin (1 µg/ml) for 12 hours were used to determine transcriptional activity of chimeric
constructs that included various regions of the BSP promoter ligated to a luciferase reporter gene.
The results of transcriptional activity obtained from three separate transfections with constructs;
pLUC basic (pLUCB) and pLUC1 to pLUC5 have been combined and the values expressed with
standard errors. Significant differences from control (relative luciferase activity of pLUCB): *P <0.1;
†
P <0.05; ‡P <0.02.
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mutation of the FRE (M-FRE) signifi-
cantly reduced the amelogenin effect
on the transcriptional activity (Fig. 6).
These results suggest that the FRE is
required as functional cis-elements for
upregulation of BSP transcription by
amelogenin.
Gel Mobility Shift Assays
To identify nuclear proteins that bind to
binding elements in pLUC3, pLUC4,
and pLUC5, double-stranded oligo-
nucleotides were end-labeled and incu-
bated with nuclear proteins (3 µg)
extracted from confluent ROS 17/2.8
cells that were either not treated (con-
trol) or treated with 1 µg/ml amelo-
genin for 3 and 12 hours. With nuclear
extracts from confluent control cultures
of ROS 17/2.8 cells, shifts of HOX
DNA-protein complexes (Fig. 7; lane 1)
and a shift of a single FRE DNA-pro-
tein complex were evident (Fig. 7,
lane 7). While HOX DNA-protein com-
plexes did not change following stim-
ulation by amelogenin (1 µg/ml) for 3
and 12 hours (Fig. 7; lanes 2 and 3),
DNA binding activity to FRE was in-
creased (Fig. 7; lanes 8 and 9). That the
Figure 4.
Regulatory elements in the proximal rat BSP promoter. A) The positions of the inverted TATA
and CCAAT boxes, a cAMP response element (CRE), an FGF2 response element (FRE), a
pituitary-specific transcription factor-1 (Pit-1), a homeobox-binding site (HOX), and a vitamin D
response element (VDRE) that overlaps the inverted TATA box are shown in the proximal
promoter region of the rat BSP gene, and a TGF-β1 activation element (TAE) overlapping an
AP2 element and a glucocorticoid response elements (GRE) overlapping the AP1 in the distal
promoter.The numbering of nucleotides is relative to the transcription start site (+1). B) The
nucleotide sequence of the rat BSP gene proximal promoter is shown from −201 to −35.
Inverted CCAAT box, CRE, FRE, NFκB, Pit-1,AP-1, and HOX are present.
Figure 5.
Effect of kinase inhibitors on transcriptional activation by amelogenin.
Transient transfection analysis of pLUC3 treated with amelogenin
(1 µg/ml) for 12 hours in ROS17/2.8 cells is shown together with the
effects of the PKC inhibitor (H7, 5 µM), PKA inhibitor (H89, 5 µM), and
tyrosine kinase inhibitor (herbimycin A; HA, 1 µM).The results obtained
from three separate transfections were combined and the values
expressed with standard errors. Significant differences compared to
controls are shown at the following probability levels: *P <0.1;
†
P <0.05; ‡P <0.01.
Figure 6.
Site mutation analysis of luciferase activities. Dinucleotide substitutions
were made within context of the homologous -116 to +60 (pLUC3)
BSP promoter fragments. M-CRE (cGACGcCG), M-FRE (GGcaAGAA),
and M-PIT (TTacAGT) were analyzed for relative promoter activity
after transfection into ROS 17/2.8 cells and examined for induction
after treatment with amelogenin (1 mg/ml) for 12 hours.The results of
transcriptional activity obtained from three separate transfections with
constructs were combined and the values expressed with standard
errors. Significant differences compared to controls are shown at the
following probability levels: *P <0.1.
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Figure 8.
Amelogenin increases the DNA binding activity recognized by TAE
sequence. Radiolabeled double-stranded inverted CCAAT (−61 CCGTGA
CCGTGATTGGCTGCTGAGA −37),TAE (−506 CAAAGCCTTGGCA
GCCCGGCTGGCT −482), and consensus NF1 (CCTTTGGCAT
GCTGCCAATAT) oligonucleotides were incubated for 20 minutes at
21°C with nuclear protein extracts (3µg) obtained from ROS 17/2.8 cells
incubated without (lanes 1, 4, and 10) or with amelogenin (1µg/ml) for
3 hours (lanes 2, 5, and 11) and 12 hours (lanes 3, 6 through 9, and 12).
DNA protein complexes were separated on 5% polyacrylamide gel in low-
ionic-strength tris-borate buffer, dried under vacuum, and exposed to an
imaging plate for quantitation using an imaging analyzer.
DNA protein complexes represent specific interactions
were indicated by competition experiments in which a
40-fold excess of HOX and FRE reduced the amount
of complex formation (Fig. 7; lanes 4 and 10). In con-
trast, CCAAT (40-fold) did not compete with complex
formation (Fig. 7; lane 6 and 12). While 40-fold excess
of the FRE slightly reduced HOX-protein complexes
formation (Fig. 7; lane 5) and 40-fold excess of the
HOX reduced FRE-protein complex formation (Fig. 7;
lane 11). When we used the inverted CCAAT sequence
as a probe, the DNA-NF-Y protein complex did not
change after stimulation by amelogenin (Fig. 8; lanes
1, 2, and 3).27,28 TAE was identified as containing
the 5’-portion of the NF-1 canonical sequence (TTGGC)
overlapping a putative AP-2 site.35 When the TAE was
incubated with the nuclear extract from control (no
treatment) and amelogenin treatment (3 hours) cul-
tures of ROS 17/2.8 cells, no significant binding was
evident (Fig. 8; lanes 4 and 5). After stimulation by
amelogenin (1 µg/ml) for 12 hours, DNA binding activ-
ity was increased (Fig. 8; lane 6). The TAE-protein
complex representing specific interaction was indicated
by competition experiments in which 40-fold excess of
TAE reduced the amount of complex formation (Fig. 8;
lane 7). In contrast, HOX and CCAAT (40-fold) did not
compete with complex formation (Fig. 8; lanes 8
and 9). When we used consensus NF-1 as a probe,
NF-1 DNA-protein complex increased after stimulation
by amelogenin for 12 hours (Fig. 8; lane 12).
DISCUSSION
These studies have shown that amelogenin increases
expression of BSP gene in osteoblastic ROS 17/2.8
cells and SBMC cells. Transduction of the amelogenin
signaling is mediated through a tyrosine kinase, which
targets nuclear proteins that bind to FRE and TAE ele-
ments in the proximal promoter of the BSP gene.
BSP is a unique marker of early osteogenic differ-
entiation that can regulate the formation of mineral
crystals.18 Our results show that amelogenin treatment
Figure 7.
Amelogenin increases the DNA binding activity recognized by the FRE
sequence. Radiolabeled double-stranded HOX (−204 TCCTCAGCCT
TCAATTAAATCCCACA −179; lanes 1 through 6) and FRE (98 TTTT
CTGGTGAGAACCCACA 79; lanes 7 through 12) oligonucleotides
were incubated for 20 minutes at 21°C with nuclear protein extracts (3
µg) obtained from ROS 17/2.8 cells incubated without (lanes 1 and 7)
or with amelogenin (1 µg/ml) for 3 hours (lanes 2 and 8) and 12 hours
(lanes 3 through 6 and 9 through 12). Competition reactions were
performed using a 40-fold molar excess of unlabeled HOX, FRE, and
CCAAT. DNA protein complexes were separated on 5% polyacrylamide
gel in low-ionic-strength tris-borate buffer, dried under vacuum and
exposed to an imaging plate for quantitation using an imaging analyzer.
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of ROS 17/2.8 cells increases the steady-state level of
BSP mRNA approximately 2.4-fold (Fig. 1). Amelo-
genin stimulated BSP promoter activity ~1.5-fold in
pLUC3 and pLUC4, and ~2.3 fold in pLUC5 constructs
(Fig. 2), which is comparable with the increases in
BSP mRNA levels. These results suggest that amelo-
genin regulates BSP mRNA expression, at least in part,
via transcriptional control. When we used SBMC cells
for luciferase assays to see the effect of amelogenin
on BSP transcription, amelogenin stimulated BSP tran-
scription (Fig. 3). Therefore, amelogenin increases
BSP expression not only in transformed ROS 17/2.8
cells but also in normal osteoprogenitors.
From transient transfection assays we initially located
the amelogenin responsive region to the proximal pro-
moter (pLUC3; nucleotides −116 to −43) of the BSP
gene (Fig. 2), which encompasses an inverted CCAAT
box (nucleotides −50 to −46), a cAMP response ele-
ment (CRE; nucleotides −75 to −68), a FGF2 response
element (FRE; nucleotides −92 to −85), and a Pit-1
(nucleotides −111 to −105) motif (Fig. 4). Luciferase
activity of pLUC5 further enhanced by amelogenin from
1.5-fold (pLUC3 and pLUC4) to 2.3-fold, suggesting
that an amelogenin response region exists not only in
pLUC3 but also in pLUC5. Although mutations of the
CRE (M-CRE) and Pit-1 (M-PIT) were without effect,
the transcriptional stimulation by amelogenin was abro-
gated in the FRE mutation (M-FRE; Fig. 6). The involve-
ment of the FRE element is further supported by gel shift
analyses in which more complexes with the FRE ele-
ment formed using nuclear extracts from amelogenin
stimulated cell (Fig. 7). The nuclear factor binding to
the FRE, which is regulated by tyrosine kinase, is the
focus of current studies because of its potential role in
regulating basal and FGF2-induced transcription of BSP
in osteoblast,31 as well as prostaglandin E2 effects.30 In
this study the tyrosine kinase inhibitor, herbimycin A
inhibited amelogenin-induced promoter activity (Fig. 5),
indicating that amelogenin increases expression of
the BSP gene through a tyrosine kinase pathway. The
nuclear factors binding to the inverted CCAAT box and
HOX did not change after stimulation by amelogenin.
Very interestingly, HOX oligonucleotides can compete
with FRE-protein complex formation (Fig. 7; lane 11),
and FRE reduced HOX-protein complexes formation
(Fig. 7; lane 5). The results might have been caused
by 3’-portion of the FRE (TGGTGAGAACCCACAGC),
which resembles the 3’-portion of the HOX sequence
(TTCAATTAAATCCCACAAT) (Fig. 4). The specific
sequence in pLUC5 is between −425 and −801, and the
identified response element in this region is the TAE.
TAE was identified as TGF-β1 activation element which
containing the 5’-portion of the NF-1 canonical se-
quence (TTGGC).35 Results of gel shift assays show
that TAE-protein complex and NF-1-protein complex
were increased by amelogenin (1 µg/ml) for 12 hours
(Fig. 8). These results indicate that amelogenin stimu-
lates BSP expression through FRE and TAE elements
in the BSP gene promoter. Further study is necessary
to investigate transcription factors that bind to FRE and
TAE, and the functional interactions of these elements.
In our previous study, EMD (50 µg/ml, 12 hours)
increased luciferase activities of pLUC4 (nucleotides
−425 to +60) and pLUC5 (nucleotides −801 to +60).
EMD regulates BSP transcription through HOX and
TAE elements in the BSP gene promoter.11 Ninety per-
cent of the protein in the EMD is amelogenin and the
remaining 10% is non-amelogenin enamel matrix pro-
teins and growth factors such as TGF-β and bone mor-
phogenetic protein (BMP).11 Discrepancy between the
activities of EMD and amelogenin on BSP transcription
might be caused by the complex components of EMD.
In this study, we have shown that amelogenin
induced BSP gene expression in osteoblast-like ROS
17/2.8 cells and rat stromal bone marrow cells. Our
results suggest that amelogenin can have a positive
effect on periodontal regeneration, such as formation
of new cementum and alveolar bone. Continued studies
necessary to investigate amelogenin effects on perio-
dontal ligament cells, which are crucial cell population
for periodontal regeneration and will be aimed at defin-
ing the transcription factors that mediate the promo-
tion of mineralization by amelogenin.
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